Ublituximab
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by PotatoBot (talk | contribs) at 17:56, 13 September 2011 (Stub sorting and placement of stub template(s): monoclonal-antibody-, antineoplastic-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 17:56, 13 September 2011 by PotatoBot (talk | contribs) (Stub sorting and placement of stub template(s): monoclonal-antibody-, antineoplastic-drug-stub. See approval. Report errors and suggestions at User talk:PotatoBot.)
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | MS4A1 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number |
Ublituximab is an immunomodulator. It binds to MS4A1.[1]
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles